Health Care • Biotechnology: Pharmaceutical Preparations
$53.67 ▲ +1.87
(+3.61%)
MKT CAP: $1.53B • VOL: 369.5K
52W L $14 52W H $66
ETON // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $80.0M | $39.0M | $31.6M |
| YoY Revenue Growth % | +104.9% | +23.3% | — |
| Gross Profit | $42.7M | $23.4M | — |
| Gross Margin % | 53.5% | 60.0% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$844.0K | -$2.6M | -$1.2M |
| Operating Margin % | -1.1% | -6.7% | -3.8% |
| Net Income (GAAP) | -$4.6M | -$3.8M | -$936.0K |
| EBITDA (Normalized) | -$577.6K | -$2.6M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $10.5M | $969.0K | $6.8M |
| Capital Expenditures (CapEx) | $333.0K | $26.0K | — |
| Free Cash Flow (FCF) | $10.2M | $943.0K | $6.8M |
| FCF Margin % | 12.7% | 2.4% | 21.5% |
| Return on Invested Capital (ROIC %) | -3.0% | -5.2% | — |
| Cash & Short-Term Equivalents | $25.9M | $14.9M | — |
| Total Debt (Short + Long Term) | $21.8M | $29.8M | — |
| Total Stockholders' Equity | $26.2M | $24.4M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ETON.